Volume 19, Number 6—June 2013
Travel-related Neisseria meningitidis Serogroup W135 Infection, France
To the Editor: A multinational outbreak of infection with Neisseria meningitidis serogroup W135 belonging to the sequence type (ST) 11 clonal complex started in the year 2000 among pilgrims to Mecca, Saudi Arabia, and their contacts and continued in 2001 in countries of sub-Saharan Africa (primarily Burkina Faso) (1). Thereafter, infection caused by these isolates decreased (2), but quadrivalent meningococcal vaccine (against serogroups A, C, Y, and W135) was recommended for pilgrims and travelers to countries in the meningitis belt of Africa, which spans sub-Saharan Africa from Ethiopia to Senegal. After 2001, infections caused by serogroup A predominated in the meningitis belt, but isolates of serogroup X also emerged (3); isolates of serogroup W135/ST11 increased again in Niger in 2010 (4).
During January 1–March 11, 2012, >4,000 suspected cases of meningococcal disease caused mainly by serogroup W135 were reported in countries of the African meningitis belt, including Benin, Burkina Faso, Mali, and Côte d’Ivoire (5). We present extensive bacteriologic and molecular characterization of N. meningitidis W135 isolates from 6 patients with meningococcal disease reported in France since January 2012; we also present typing data from 8 cases of meningitis in Côte d’Ivoire. None of the patients had received meningococcal vaccine.
The cases in France were neither epidemiologically nor geographically linked; 4 were in residents of the Paris region. All cases were linked to recent travel to sub-Saharan Africa by the patient or patient contacts; 4 patients reported recent travel to Benin, Senegal, or Mali (Table). The 2 other cases were in a 4-month-old infant whose father had returned from Senegal 2 weeks before the onset of the disease and in a 5-year-old child who had several family members who visited Mali regularly, although no recent travel was documented. The delay between the return to France and the onset of the disease was <5 days except for 1 patient (17 days).
N. meningitidis isolates were recovered from blood, cerebrospinal fluid, or articular fluid from all 6 patients in France (Table). Two patients had septicemia after bronchopneumonia, but no respiratory samples were available. One patient had arthritis that was also described in his sister, but no samples were available from the sister. Extrameningeal forms of illness caused by W135/ST11 isolates have been described (6). For the patients in Côte d’Ivoire, bacteria were isolated from cerebrospinal fluid during weeks 5–8 in 2012; the patients lived in 3 districts of the country (Kouto, Korhogo, and Tengrela). Mean age was 20.9 years (range 0.33–62) for the patients in France and 16.25 years (range 1–65) for those in Côte d’Ivoire.
Molecular typing was performed by multilocus sequence typing (MLST) using the PubMLST database (http://pubmlst.org/neisseria); typing included the 7 usual genes of MLST, PorA variable regions 1 and 2, and penA and fetA genes. Results were obtained by using cultured bacteria for all but 1 case in France. All isolates from France and Côte d’Ivoire shared the same tested markers. Eight other cases of infection with serogroup W135 were found in France during the same period, but the patients had no travel history, and all isolates showed different markers (M.-K. Taha, unpub. data).
Serogroup W135 strains are widely distributed worldwide; the emergence of these strains during the 2000s corresponded to a clonal expansion of 1 clone within the ST11 complex (7). The subsequent decline of W135/ST11 strains was associated with increased isolate diversification (8), which suggests a selective restriction of the dominant circulating strain (2). In France, the W135/ST11 strain was rare after 2005; no cases were culture confirmed in 2010, and the 2 cases that were confirmed in 2011 showed the FetA2-19 marker. However, isolates from Africa during 2000–2011 frequently showed the FetA1 marker; in sub-Saharan Africa, the decline of W135/ST11 isolates was also associated with isolates showing diversified the FetA marker (M.-K. Taha, unpub. data). The reemergence in 2012 of W135/ST11 strains that had FetA1-1 markers suggests an antigenic shift that may have involved membrane proteins other than FetA or other surface structures, such as the lipooligosasccharide. Such antigenic shifts were associated with increased incidence of serogroup C and serogroup Y meningococcal disease in the United States (9). Antigenic shift could be a marker of changes in virulence and transmission of meningococcal isolates. Extensive molecular typing of meningococcal isolates is more likely to detect antigenic shifts and escape variants that may undergo clonal expansion and therefore should be employed in outbreak investigations. Enhanced surveillance was setup in France to identify imported W135 cases.
Our findings indicate that travelers to the meningitis belt of sub-Saharan Africa may be at risk for infection with N. meningitidis of serogroup W135. A vaccination campaign using the meningococcal A conjugate vaccine is ongoing in this region (10), but a conjugate bivalent vaccine that includes W135 should also be considered. Vaccination of travelers to this region with quadrivalent meningococcal vaccine should be recommended.
Information regarding the patients and their contacts were provided by the clinicians, the French Institute for Public Health Surveillance (www.invs.sante.fr), and the Regional Health Agencies of Pays-de-Loire, Rhône-Alpes and Ile-de-France. In Côte d’Ivoire, the work was supported by the Agence Médecine Préventive and the mobile laboratory; patient information was provided by clinicians at health districts and the National Institute of Public Health.
- Parent du Châtelet I, Traore Y, Gessner BD, Antignac A, Naccro B, Njanpop-Lafourcade BM, Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing. Clin Infect Dis. 2005;40:17–25.
- Traoré Y, Njanpop-Lafourcade BM, Adjogble KL, Lourd M, Yaro S, Nacro B, The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002–2005. Clin Infect Dis. 2006;43:817–22.
- Meningitis in Chad. Niger and Nigeria: 2009 epidemic season. Wkly Epidemiol Rec. 2010;85:47–63 .
- Collard JM, Maman Z, Yacouba H, Djibo S, Nicolas P, Jusot JF, Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis. 2010;16:1496–8.
- World Health Organization. Meningococcal disease: situation in the African meningitis belt. 2012 Mar 23 [cited 2013 Mar 18]. http://www.who.int/csr/don/2012_03_23/en/index.html
- Vienne P, Ducos-Galand M, Guiyoule A, Pires R, Giorgini D, Taha MK, The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis. 2003;37:1639–42.
- Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha MK, Ajello GW, Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis. 2002;185:1596–605.
- Taha MK, Giorgini D, Ducos-Galand M, Alonso JM. Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. J Clin Microbiol. 2004;42:4158–63.
- Harrison LH, Jolley KA, Shutt KA, Marsh JW, O’Leary M, Sanza LT, ; Maryland Emerging Infections Program. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis. 2006;193:1266–74.
- Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine. 2009;27(Suppl 2):B13–9.
Suggested citation for this article: Taha M-K, Kacou-N’Douba A, Hong E, Deghmane AE, Giorgini D, Okpo SL, et al. Travel-related Neisseria meningitidis serogroup W135 infection, France [letter]. Emerg Infect Dis [Internet]. 2013 Jun [date cited]. http://dx.doi.org/10.3201/eid1906.120515
- Page created: May 20, 2013
- Page last updated: May 20, 2013
- Page last reviewed: May 20, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)